Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 582

1.

Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.

Molica S, Giannarelli D, Montserrat E.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):423-430. doi: 10.1016/j.clml.2019.03.014. Epub 2019 Mar 23.

PMID:
31027992
2.

Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia.

Molica S, Montserrat E.

Lancet Haematol. 2019 Feb;6(2):e65-e66. doi: 10.1016/S2352-3026(18)30222-9. No abstract available.

PMID:
30709435
3.

Critical molecular pathways in CLL therapy.

Ferrer G, Montserrat E.

Mol Med. 2018 Mar 15;24(1):9. doi: 10.1186/s10020-018-0001-1. Review.

4.

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, Moreno C, Robak T, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT).

Blood. 2018 Aug 30;132(9):892-902. doi: 10.1182/blood-2018-01-826008. Epub 2018 Jul 11. Review.

PMID:
29997221
5.

Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.

Moreno C, Delgado J, Byrd JC, Zvagelsky WL, Suzuki S, Hsu E, James DF, Montserrat E.

Br J Haematol. 2019 Apr;185(1):148-150. doi: 10.1111/bjh.15397. Epub 2018 May 31. No abstract available.

6.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.

7.

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia.

Mozas P, Rivas-Delgado A, Baumann T, Villamor N, Ortiz-Maldonado V, Aymerich M, Costa D, Navarro A, Giné E, López-Guillermo A, Montserrat E, Delgado J.

Blood Cancer J. 2018 Jan 16;8(1):10. doi: 10.1038/s41408-017-0044-5. No abstract available.

8.

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.

Marsilio S, Khiabanian H, Fabbri G, Vergani S, Scuoppo C, Montserrat E, Shpall EJ, Hadigol M, Marin P, Rai KR, Rabadan R, Devereux S, Pasqualucci L, Chiorazzi N.

Leukemia. 2018 Apr;32(4):1041-1044. doi: 10.1038/leu.2017.343. Epub 2017 Dec 5. No abstract available.

9.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E.

Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17.

10.

FcγRIIb expression in early stage chronic lymphocytic leukemia.

Bosch R, Mora A, Vicente EP, Ferrer G, Jansà S, Damle R, Gorlatov S, Rai K, Montserrat E, Nomdedeu J, Pratcorona M, Blanco L, Saavedra S, Garrido A, Esquirol A, Garcia I, Granell M, Martino R, Delgado J, Sierra J, Chiorazzi N, Moreno C.

Leuk Lymphoma. 2017 Nov;58(11):2642-2648. doi: 10.1080/10428194.2017.1307981. Epub 2017 Apr 4.

11.

Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.

Molica S, Giannarelli D, Mirabelli R, Levato L, Gentile M, Morabito F, Montserrat E.

Am J Hematol. 2017 Jun;92(6):E91-E93. doi: 10.1002/ajh.24707. Epub 2017 Mar 24. No abstract available.

12.

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.

Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E.

Am J Hematol. 2017 Apr;92(4):375-380. doi: 10.1002/ajh.24660. Epub 2017 Feb 13.

13.

CLL: when the target of treatment is disease-related symptoms.

Molica S, Montserrat E.

Lancet Haematol. 2017 Feb;4(2):e57-e58. doi: 10.1016/S2352-3026(16)30186-7. Epub 2017 Jan 12. No abstract available.

PMID:
28089237
14.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

15.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Review.

16.

Present and future of personalized medicine in CLL.

Montserrat E, Bauman T, Delgado J.

Best Pract Res Clin Haematol. 2016 Mar;29(1):100-110. doi: 10.1016/j.beha.2016.08.009. Epub 2016 Aug 12. Review.

PMID:
27742064
17.

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v143-v144. No abstract available.

PMID:
27664254
18.

Maintenance therapy in chronic lymphocytic leukaemia.

Delgado J, Montserrat E.

Lancet Haematol. 2016 Sep;3(9):e399-400. doi: 10.1016/S2352-3026(16)30081-3. Epub 2016 Aug 1. No abstract available.

PMID:
27570083
19.

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?

Montserrat E, Dreger P.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S74-81. doi: 10.1016/j.clml.2016.02.013. Review.

PMID:
27521330
20.

CLL: ibrutinib and transplantation ride together.

Montserrat E, Delgado J.

Bone Marrow Transplant. 2016 Jun;51(6):769-70. doi: 10.1038/bmt.2016.118. Epub 2016 May 9. No abstract available.

PMID:
27159178
21.

Reply to the letter to the editor 'Survival in young adults diagnosed with follicular lymphoma' by Calvo et al.

Conconi A, Montoto S, Montserrat E, Zucca E.

Ann Oncol. 2016 Jun;27(6):1173. doi: 10.1093/annonc/mdw058. Epub 2016 Feb 18. No abstract available.

PMID:
27002104
22.

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Pospisilova S, Sutton LA, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, Ghia P; European Research Initiative on CLL (ERIC).

Haematologica. 2016 Mar;101(3):263-5. doi: 10.3324/haematol.2015.139246. No abstract available.

23.

Transplantation in CLL: what we can learn from a dinosaur.

Dreger P, Montserrat E.

Bone Marrow Transplant. 2016 Jun;51(6):765-6. doi: 10.1038/bmt.2016.27. Epub 2016 Feb 29. No abstract available.

PMID:
26926227
24.

Primary CNS lymphoma: in search of the evidence.

Montserrat E.

Lancet Haematol. 2015 Jun;2(6):e227-8. doi: 10.1016/S2352-3026(15)00091-5. Epub 2015 Jun 3. No abstract available.

PMID:
26688231
25.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P.

Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.

26.

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.

Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Rozman M, Aymerich M, López C, Costa D, Carrió A, Villamor N, Montserrat E.

Br J Haematol. 2016 Jan;172(1):48-55. doi: 10.1111/bjh.13788. Epub 2015 Nov 12.

PMID:
26559905
27.

Life expectancy of young adults with follicular lymphoma.

Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F, Moccia A, Rancoita PM, Gribben J, Cavalli F, Gaidano G, Lister TA, Montserrat E, Ghielmini M, Zucca E.

Ann Oncol. 2015 Nov;26(11):2317-22. doi: 10.1093/annonc/mdv376. Epub 2015 Sep 11.

PMID:
26362567
28.

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2015 Sep;26 Suppl 5:v78-84. doi: 10.1093/annonc/mdv303. No abstract available.

PMID:
26314781
29.

Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation.

Montserrat E, Dreger P.

J Clin Oncol. 2015 May 10;33(14):1527-9. doi: 10.1200/JCO.2014.60.3282. Epub 2015 Apr 13. No abstract available.

PMID:
25870086
30.

Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?

Dreger P, Montserrat E; European Society for Blood and Marrow Transplantation (EBMT); European Research Initiative on CLL (ERIC).

Curr Hematol Malig Rep. 2015 Mar;10(1):59-64. doi: 10.1007/s11899-014-0242-1. Review.

PMID:
25651976
31.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.

32.

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT).

Blood. 2014 Dec 18;124(26):3841-9. doi: 10.1182/blood-2014-07-586826. Epub 2014 Oct 9. Review.

33.

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).

Haematologica. 2014 Aug;99(8):1285-91. doi: 10.3324/haematol.2013.101170.

34.

Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model.

Baumann T, Delgado J, Santacruz R, Martínez-Trillos A, Royo C, Navarro A, Pinyol M, Rozman M, Pereira A, Villamor N, Aymerich M, López C, Carrió A, Montserrat E.

Haematologica. 2014 Oct;99(10):1599-604. doi: 10.3324/haematol.2014.107326. Epub 2014 Jun 27.

35.

XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells.

Moreno-Martínez D, Nomdedeu M, Lara-Castillo MC, Etxabe A, Pratcorona M, Tesi N, Díaz-Beyá M, Rozman M, Montserrat E, Urbano-Ispizua A, Esteve J, Risueño RM.

Oncotarget. 2014 Jun 30;5(12):4337-46.

36.

New treatment options for chronic lymphocytic leukemia.

Delgado J, Baumann T, Santacruz R, Montserrat E.

Expert Opin Pharmacother. 2014 Apr;15(6):823-32. doi: 10.1517/14656566.2014.891017. Epub 2014 Feb 22. Review.

PMID:
24559127
37.

B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.

Ferrer G, Bosch R, Hodgson K, Tejero R, Roué G, Colomer D, Montserrat E, Moreno C.

Br J Haematol. 2014 Feb;164(4):570-8. doi: 10.1111/bjh.12645. Epub 2013 Nov 18.

PMID:
24245956
38.

Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration.

Delgado J, Ghita G, Baumann T, Santacruz R, Dlouhy I, Aymerich M, Rozman M, Creus N, Pereira A, Montserrat E.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):73-9. doi: 10.1016/j.clml.2013.08.003. Epub 2013 Oct 12.

PMID:
24126217
39.

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F.

Blood. 2013 Dec 5;122(24):3951-9. doi: 10.1182/blood-2013-05-502773. Epub 2013 Oct 11.

40.

CLL therapy: the increasing importance of predictive markers.

Montserrat E.

Oncology (Williston Park). 2012 Nov;26(11):1064-6. No abstract available.

41.

MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia.

Ferrer G, Navarro A, Hodgson K, Aymerich M, Pereira A, Baumann T, Monzo M, Moreno C, Montserrat E.

Leuk Lymphoma. 2013 Sep;54(9):2016-22. doi: 10.3109/10428194.2012.763123. Epub 2013 Jan 29.

PMID:
23286334
42.

Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.

Burger JA, Montserrat E.

Blood. 2013 Feb 28;121(9):1501-9. doi: 10.1182/blood-2012-08-452607. Epub 2012 Dec 20. Review.

43.

[Hepatic resection in hepatocarcinoma: a comparative study between patients under and over 70 years-old].

Murillo A, Artigas V, González JA, Gallego A, Montserrat E, Rodriguez M, Trías M.

Cir Esp. 2013 Apr;91(4):224-30. doi: 10.1016/j.ciresp.2012.07.016. Epub 2012 Dec 13. Spanish.

PMID:
23245933
44.

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma.

Ann Oncol. 2013 Mar;24(3):561-76. doi: 10.1093/annonc/mds517. Epub 2012 Nov 21.

45.

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P; European Research Initiative in CLL.

Leukemia. 2013 Jan;27(1):142-9. doi: 10.1038/leu.2012.216. Epub 2012 Jul 31.

PMID:
23041722
46.

Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations.

López C, Delgado J, Costa D, Conde L, Ghita G, Villamor N, Navarro A, Cazorla M, Gómez C, Arias A, Muñoz C, Baumann T, Rozman M, Aymerich M, Colomer D, Cobo F, Campo E, López-Guillermo A, Montserrat E, Carrió A.

Genes Chromosomes Cancer. 2012 Sep;51(9):881-9. doi: 10.1002/gcc.21972. Epub 2012 May 23.

PMID:
22619094
47.

Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapy.

Delgado J, Baumann T, Ghita G, Montserrat E.

Curr Pharm Des. 2012;18(23):3356-62. Review.

PMID:
22591384
48.

Comment on "Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors".

Ferrer G, Moreno C, Montserrat E.

J Immunol. 2012 Apr 1;188(7):2930-1; author reply 2931. doi: 10.4049/jimmunol.1290009. No abstract available.

49.

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.

Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).

Leukemia. 2012 Jul;26(7):1458-61. doi: 10.1038/leu.2012.25. Epub 2012 Feb 2. Review.

PMID:
22297721
50.

Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.

López-Guerra M, Xargay-Torrent S, Pérez-Galán P, Saborit-Villarroya I, Rosich L, Villamor N, Aymerich M, Roué G, Campo E, Montserrat E, Colomer D.

Leukemia. 2012 Jun;26(6):1429-32. doi: 10.1038/leu.2011.364. Epub 2011 Dec 20. No abstract available.

PMID:
22182921

Supplemental Content

Loading ...
Support Center